Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein

Cell Reports

Volumn 14, Issue 11, 2016, Pages 2695-2706

  Behrens, Anna Janina ^a   Vasiljevic, Snezana ^a   Pritchard, Laura K ^a   Harvey, David J ^a   Andev, Rajinder S ^b   Krumm, Stefanie A ^b   Struwe, Weston B ^a   Cupo, Albert ^c   Kumar, Abhinav ^a   Zitzmann, Nicole ^a   Seabright, Gemma E ^a   Kramer, Holger B ^a   Spencer, Daniel I R ^d   Royle, Louise ^d   Lee, Jeong Hyun ^e   Klasse, Per J ^c   Burton, Dennis R ^f,g   Wilson, Ian A ^e,h   Ward, Andrew B ^e   Sanders, Rogier W ^c,i   Moore, John P ^c   Doores, Katie J ^b   Crispin, Max ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Culham Science Centre   (United Kingdom)

^e International AIDS Vaccine Initiative Neutralizing Antibody Center   (United States)

^f Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h SCRIPPS RESEARCH INSTITUTE   (United States)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; GLYCOPEPTIDE; GLYCOPROTEIN GP 120; POLYSACCHARIDE; RECOMBINANT PROTEIN;

ANTIGENICITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; VIRUS NEUTRALIZATION; AFFINITY CHROMATOGRAPHY; BIOSYNTHESIS; CHEMISTRY; GENETICS; GLYCOSYLATION; HEK293 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM;

ANTIBODIES, NEUTRALIZING; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLYCOPEPTIDES; GLYCOSYLATION; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; POLYSACCHARIDES; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84959932564     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.058     Document Type: Article

References (66)

1. Amin M.N., McLellan J.S., Huang W., Orwenyo J., Burton D.R., Koff W.C., Kwong P.D., Wang L.-X. Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat. Chem. Biol. 2013, 9:521-526.
2. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 2000, 74:627-643.
3. Blattner C., Lee J.H., Sliepen K., Derking R., Falkowska E., de la Peña A.T., Cupo A., Julien J.P., van Gils M., Lee P.S., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014, 40:669-680.
4. Bonomelli C., Doores K.J., Dunlop D.C., Thaney V., Dwek R.A., Burton D.R., Crispin M., Scanlan C.N. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 2011, 6:e23521.
5. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
6. Chung N.P.Y., Matthews K., Kim H.J., Ketas T.J., Golabek M., de Los Reyes K., Korzun J., Yasmeen A., Sanders R.W., Klasse P.J., et al. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology 2014, 11:33.
7. Coutu M., Finzi A. HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. J. Virol. Methods 2015, 215-216:37-44.
8. Crispin M., Doores K.J. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr. Opin. Virol. 2015, 11:63-69.
9. Depetris R.S., Julien J.P., Khayat R., Lee J.H., Pejchal R., Katpally U., Cocco N., Kachare M., Massi E., David K.B., et al. Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J. Biol. Chem. 2012, 287:24239-24254.
10. Doores K.J. The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J. 2015, 282:4679-4691.
11. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 2010, 84:10510-10521.
12. Doores K.J., Bonomelli C., Harvey D.J., Vasiljevic S., Dwek R.A., Burton D.R., Crispin M., Scanlan C.N. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. USA 2010, 107:13800-13805.
13. Doores K.J., Kong L., Krumm S.A., Le K.M., Sok D., Laserson U., Garces F., Poignard P., Wilson I.A., Burton D.R. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J. Virol. 2015, 89:1105-1118.
14. Falkowska E., Le K.M., Ramos A., Doores K.J., Lee J.H., Blattner C., Ramirez A., Derking R., van Gils M.J., Liang C.-H., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014, 40:657-668.
15. Garces F., Sok D., Kong L., McBride R., Kim H.J., Saye-Francisco K.F., Julien J.-P., Hua Y., Cupo A., Moore J.P., et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 2014, 159:69-79.
16. Garces F., Lee J.H., de Val N., Torrents de la Pena A., Kong L., Puchades C., Hua Y., Stanfield R.L., Burton D.R., Moore J.P., et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 2015, 43:1053-1063.
17. Go E.P., Hewawasam G., Liao H.-X., Chen H., Ping L.-H., Anderson J.A., Hua D.C., Haynes B.F., Desaire H. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J. Virol. 2011, 85:8270-8284.
18. Go E.P., Liao H.-X., Alam S.M., Hua D., Haynes B.F., Desaire H. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J. Proteome Res. 2013, 12:1223-1234.
19. Go E.P., Herschhorn A., Gu C., Castillo-Menendez L., Zhang S., Mao Y., Chen H., Ding H., Wakefield J.K., Hua D., et al. Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140. J. Virol. 2015, 89:8245-8257.
20. Guttman M., Garcia N.K., Cupo A., Matsui T., Julien J.P., Sanders R.W., Wilson I.A., Moore J.P., Lee K.K. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 2014, 22:974-984.
21. Harvey D.J., Sobott F., Crispin M., Wrobel A., Bonomelli C., Vasiljevic S., Scanlan C.N., Scarff C.A., Thalassinos K., Scrivens J.H. Ion mobility mass spectrometry for extracting spectra of N-glycans directly from incubation mixtures following glycan release: application to glycans from engineered glycoforms of intact, folded HIV gp120. J. Am. Soc. Mass Spectrom. 2011, 22:568-581.
22. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., Forthal D.N., Koff W.C., Poignard P., Watkins D.I., Burton D.R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 2010, 84:1302-1313.
23. Huang J., Kang B.H., Pancera M., Lee J.H., Tong T., Feng Y., Imamichi H., Georgiev I.S., Chuang G.Y., Druz A., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
24. Julien J.-P., Lee J.H., Cupo A., Murin C.D., Derking R., Hoffenberg S., Caulfield M.J., King C.R., Marozsan A.J., Klasse P.J., et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. USA 2013, 110:4351-4356.
25. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
26. Khayat R., Lee J.H., Julien J.-P., Cupo A., Klasse P.J., Sanders R.W., Moore J.P., Wilson I.A., Ward A.B. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J. Virol. 2013, 87:9865-9872.
27. Klasse P.J., Depetris R.S., Pejchal R., Julien J.-P., Khayat R., Lee J.H., Marozsan A.J., Cupo A., Cocco N., Korzun J., et al. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J. Virol. 2013, 87:9873-9885.
28. Kong L., Sheppard N.C., Stewart-Jones G.B., Robson C.L., Chen H., Xu X., Krashias G., Bonomelli C., Scanlan C.N., Kwong P.D., et al. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J. Mol. Biol. 2010, 403:131-147.
29. Kong L., Lee J.H., Doores K.J., Murin C.D., Julien J.P., McBride R., Liu Y., Marozsan A., Cupo A., Klasse P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
30. Kong L., Torrents de la Peña A., Deller M.C., Garces F., Sliepen K., Hua Y., Stanfield R.L., Sanders R.W., Wilson I.A. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta Crystallogr. D Biol. Crystallogr. 2015, 71:2099-2108.
31. Kovacs J.M., Noeldeke E., Ha H.J., Peng H., Rits-Volloch S., Harrison S.C., Chen B. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc. Natl. Acad. Sci. USA 2014, 111:18542-18547.
32. Lasky L.A., Groopman J.E., Fennie C.W., Benz P.M., Capon D.J., Dowbenko D.J., Nakamura G.R., Nunes W.M., Renz M.E., Berman P.W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986, 233:209-212.
33. Lee J.H., de Val N., Lyumkis D., Ward A.B. Model building and refinement of a natively glycosylated HIV-1 Env protein by high-resolution cryoelectron microscopy. Structure 2015, 23:1943-1951.
34. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 1990, 265:10373-10382.
35. Lyumkis D., Julien J.P., de Val N., Cupo A., Potter C.S., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
36. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
37. Mathys L., François K.O., Quandte M., Braakman I., Balzarini J. Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS ONE 2014, 9:e101181.
38. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.-P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
39. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.Y., Swiderek K., Weisgrau K.L., Piaskowski S.M., Bergman Z., Watkins D.I., Poignard P., Burton D.R. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 2012, 109:18921-18925.
40. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 2005, Chapter 12:11.
41. Moore J.P., Willey R.L., Lewis G.K., Robinson J., Sodroski J. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J. Virol. 1994, 68:6836-6847.
42. Mouquet H., Scharf L., Euler Z., Liu Y., Eden C., Scheid J.F., Halper-Stromberg A., Gnanapragasam P.N.P., Spencer D.I.R., Seaman M.S., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 2012, 109:E3268-E3277.
43. Neville D.C., Dwek R.A., Butters T.D. Development of a single column method for the separation of lipid- and protein-derived oligosaccharides. J. Proteome Res. 2009, 8:681-687.
44. Pabst M., Chang M., Stadlmann J., Altmann F. Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. Biol. Chem. 2012, 393:719-730.
45. Pancera M., Shahzad-Ul-Hussan S., Doria-Rose N.A., McLellan J.S., Bailer R.T., Dai K., Loesgen S., Louder M.K., Staupe R.P., Yang Y., et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 2013, 20:804-813.
46. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.-S., Wang S.-K., Stanfield R.L., Julien J.-P., Ramos A., Crispin M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
47. Pritchard L.K., Harvey D.J., Bonomelli C., Crispin M., Doores K.J. Cell- and protein-directed glycosylation of native cleaved HIV-1 envelope. J. Virol. 2015, 89:8932-8944.
48. Pritchard L.K., Spencer D.I., Royle L., Bonomelli C., Seabright G.E., Behrens A.J., Kulp D.W., Menis S., Krumm S.A., Dunlop D.C., et al. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat. Commun. 2015, 6:7479.
49. Pritchard L.K., Spencer D.I., Royle L., Vasiljevic S., Krumm S.A., Doores K.J., Crispin M. Glycan microheterogeneity at the PGT135 antibody recognition site on HIV-1 gp120 reveals a molecular mechanism for neutralization resistance. J. Virol. 2015, 89:6952-6959.
50. Pritchard L.K., Vasiljevic S., Ozorowski G., Seabright G.E., Cupo A., Ringe R., Kim H.J., Sanders R.W., Doores K.J., Burton D.R., et al. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep. 2015, 11:1604-1613.
51. Ringe R.P., Sanders R.W., Yasmeen A., Kim H.J., Lee J.H., Cupo A., Korzun J., Derking R., van Montfort T., Julien J.-P., et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc. Natl. Acad. Sci. USA 2013, 110:18256-18261.
52. Ringe R.P., Yasmeen A., Ozorowski G., Go E.P., Pritchard L.K., Guttman M., Ketas T.A., Cottrell C.A., Wilson I.A., Sanders R.W., et al. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers. J. Virol. 2015, 89:12189-12210.
53. Sanders R.W., Vesanen M., Schuelke N., Master A., Schiffner L., Kalyanaraman R., Paluch M., Berkhout B., Maddon P.J., Olson W.C., et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 2002, 76:8875-8889.
54. Sanders R.W., Derking R., Cupo A., Julien J.P., Yasmeen A., de Val N., Kim H.J., Blattner C., de la Peña A.T., Korzun J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013, 9:e1003618.
55. Sanders R.W., van Gils M.J., Derking R., Sok D., Ketas T.J., Burger J.A., Ozorowski G., Cupo A., Simonich C., Goo L., et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015, 349:aac4223.
56. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J. Virol. 2002, 76:7306-7321.
57. Scharf L., Scheid J.F., Lee J.H., West A.P., Chen C., Gao H., Gnanapragasam P.N.P., Mares R., Seaman M.S., Ward A.B., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014, 7:785-795.
58. Sok D., Doores K.J., Briney B., Le K.M., Saye-Francisco K.L., Ramos A., Kulp D.W., Julien J.P., Menis S., Wickramasinghe L., et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 2014, 6:236ra63.
59. Townsley S., Li Y., Kozyrev Y., Cleveland B., Hu S.L. Conserved role of an N-linked glycan on the surface antigen of human immunodeficiency virus type 1 modulating virus sensitivity to broadly neutralizing antibodies against the receptor and coreceptor binding sites. J. Virol. 2015, 90:829-841.
60. Wada Y. Glycan profiling: label-free analysis of glycoproteins. Methods Mol. Biol. 2013, 951:245-253.
61. Walker L.M., Phogat S.K., Chan-Hui P.-Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. Protocol G Principal Investigators.
62. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., Wang S.-K., Ramos A., Chan-Hui P.-Y., Moyle M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470. Protocol G Principal Investigators.
63. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
64. Woods R.J., Pathiaseril A., Wormald M.R., Edge C.J., Dwek R.A. The high degree of internal flexibility observed for an oligomannose oligosaccharide does not alter the overall topology of the molecule. Eur. J. Biochem. 1998, 258:372-386.
65. Wu X., Parast A.B., Richardson B.A., Nduati R., John-Stewart G., Mbori-Ngacha D., Rainwater S.M., Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 2006, 80:835-844.
66. Zhu X., Borchers C., Bienstock R.J., Tomer K.B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 2000, 39:11194-11204.